Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OXFD Oxford Immunotec Global (OXFD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Oxford Immunotec Global Stock (NASDAQ:OXFD) 30 days 90 days 365 days Advanced Chart Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get OXFD alerts:Sign Up Key Stats Today's Range$21.99▼$21.9950-Day Range$21.88▼$21.9952-Week Range$8.37▼$23.11VolumeN/AAverage Volume1.10 million shsMarket Capitalization$570.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.Read More… 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Receive OXFD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter. Email Address OXFD Stock News HeadlinesA Game-Changing VaccineOctober 30, 2024 | time.comOxford Farming Conference announces 2025 Inspire DelegatesOctober 18, 2024 | msn.comWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.November 21, 2024 | DTI (Ad)Nigeria rolls out new Oxford R21 malaria vaccineOctober 18, 2024 | reuters.comUniversity of Oxford scientist addresses UN on tackling antimicrobial resistanceOctober 1, 2024 | msn.comTuberculosis Diagnostics Test Market to hit USD 3.7 billion by 2032, says Global Market Insights Inc.September 24, 2024 | finance.yahoo.comBoat Race: Oxford rowers criticise sewage levels in River ThamesSeptember 16, 2024 | bbc.co.ukStocks to Watch: Oxford Industries, Mobile Infrastructure, Champions OncologySeptember 11, 2024 | marketwatch.comSee More Headlines OXFD Stock Analysis - Frequently Asked Questions How were Oxford Immunotec Global's earnings last quarter? Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The firm had revenue of $19.44 million for the quarter, compared to analysts' expectations of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%. What other stocks do shareholders of Oxford Immunotec Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO). Company Calendar Last Earnings11/03/2020Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OXFD CUSIPN/A CIK1586049 Webwww.oxfordimmunotec.com Phone44-0-12-3544-2780FaxN/AEmployees273Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,810,000.00 Net Margins-30.51% Pretax MarginN/A Return on Equity-8.39% Return on Assets-7.63% Debt Debt-to-Equity RatioN/A Current Ratio15.96 Quick Ratio14.85 Sales & Book Value Annual Sales$73.71 million Price / Sales7.75 Cash Flow$0.02 per share Price / Cash Flow1,408.78 Book Value$8.08 per share Price / Book2.72Miscellaneous Outstanding Shares25,962,000Free FloatN/AMarket Cap$570.90 million OptionableNot Optionable Beta1.42 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:OXFD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Immunotec Global PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Immunotec Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.